These combined effects help improve glycaemic control and often lead to weight loss, which can be particularly beneficial for individuals with type 2 diabetes who are overweight or obese
Dietary interventions should focus on sustainable, balanced eating patterns rather than restrictive diets
By being informed about the conditions under which weight loss medications are covered, individuals can better navigate their healthcare options
Importantly, the observed attenuation of incremental benefit at higher doses for both agents suggests diminishing returns with dose escalation, reinforcing the need to balance expected benefit against treatment burden and patient-specific factors
Effects of alagebrium, an advanced glycation end-product breaker, in patients with chronic heart failure: Study design and baseline characteristics of the BENEFICIAL trial
10.3233/bd-210043 94 SanoM.HirakawaS.SuzukiM.SakabeJ